Drug Trial Radar · NCT05951179
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
131
Planned (sponsor's estimate)
Start
Sep 15, 2023
Primary completion
Oct 2031
Study completion Mar 2032
Sponsor
- Lead sponsor
- Protara TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF. Participants will be enrolled into one of 2 cohorts: Cohort A: * Participants with CIS (± Ta/T1) who are BCG naive, or * Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis Cohort B: * Participants who are BCG unresponsive
Conditions
- Non-muscle Invasive Bladder Cancer
Interventions
TARA-002Biological
All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, 18 and 24. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 27 until Month 60.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002Time frame: Month 3 to Month 60
Locations
78 sites in 7 countries. Site status is shown where the registry gives one.
Urology Centers of Alabama
Homewood, Alabama · Recruiting
Mayo Clinic
Phoenix, Arizona · Recruiting
East Valley Urology Center of Arizona
Queen Creek, Arizona · Recruiting
Arkansas Urology
Little Rock, Arkansas · Recruiting
Michael Oefelein Clinical Trials
Bakersfield, California · Recruiting
Urology Group of Southern California
Los Angeles, California · Terminated
University of California Irvine Medical Center
Orange, California · Recruiting
Genesis Research
San Diego, California · Withdrawn
Genesis Research LLC
Torrance, California · Recruiting
Colorado University - Anshutz
Aurora, Colorado · Recruiting
AdventHealth Medical Group Urology of Denver
Denver, Colorado · Recruiting
Advanced Urology
Lakewood, Colorado · Recruiting
Urology Associates of Denver
Lone Tree, Colorado · Recruiting
University of Florida Health Jacksonville
Gainesville, Florida · Withdrawn
Mayo Clinic
Jacksonville, Florida · Recruiting
Comprehensive Urologic Care
Lake Barrington, Illinois · Recruiting
Southern Urology
Lafayette, Louisiana · Recruiting
Ochsner Health LSU - Regional Urology
Shreveport, Louisiana · Withdrawn
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Greater Boston Urology, LLC
Plymouth, Massachusetts · Recruiting
Minnesota Urology, Woodbury
Bloomington, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Renown Regional Medical Center
St Louis, Missouri · Recruiting
Specialty Clinic Research of St. Louis
St Louis, Missouri · Recruiting
AccuMed Research Associates
Garden City, New York · Terminated
Laura & Isaac Perlmutter Cancer Center - NYU Langone Health
New York, New York · Recruiting
University of Rochester, Department of Urology
Rochester, New York · Recruiting
Associated Medical Professionals of NY, PLLC
Syracuse, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Cleveland Clinic Main Campus, Cleveland
Cleveland, Ohio · Recruiting
University of Toledo
Toledo, Ohio · Withdrawn
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Conrad Person Clinic
Memphis, Tennessee · Recruiting
Urology Associates PC
Nashville, Tennessee · Recruiting
Amarillo Urology Research
Amarillo, Texas · Withdrawn
Urology Partners of North Texas
Arlington, Texas · Recruiting
Urology Austin, LLC
Austin, Texas · Recruiting
Houston Metro Urology
Houston, Texas · Recruiting
Houston Methodist Hospital
Houston, Texas · Recruiting
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.